KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada MISSISSAUGA, ON, Oct. 28, 2020 /CNW/ – KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, FIRDAPSE® (amifampridine phosphate), the first amifampridine product approved in Canada, … Continue reading KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes  Finerenone specifically addresses MR overactivation, a key driver of disease progression   … Continue reading Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Good News eBook FINDING THE LIGHT is Vitamin ‘D’ for the Soul

Good News eBook FINDING THE LIGHT is Vitamin ‘D’ for the Soul FindingTheLight.ca TORONTO, Oct. 28, 2020 /CNW/ – The 200+ page eBook is a time capsule chronicle. It is not a news story or a political piece. It is a one-of-a-kind positive resource comprised of bite-sized essays, breathtaking photographs and poetry, which illuminates the real and relatable thoughts, fears and revelations of 70+ … Continue reading Good News eBook FINDING THE LIGHT is Vitamin ‘D’ for the Soul

CMA-Deloitte report reinforces the urgent need to reduce the backlog of medical services affecting millions of Ontario patients

CMA-Deloitte report reinforces the urgent need to reduce the backlog of medical services affecting millions of Ontario patients TORONTO, Oct. 26, 2020 /CNW/ – With COVID-19 cases rising, the findings in the Deloitte report for the Canadian Medical Association (CMA) on the COVID-19-induced surgical backlog reinforce the serious concerns about patient care that the Ontario … Continue reading CMA-Deloitte report reinforces the urgent need to reduce the backlog of medical services affecting millions of Ontario patients

MAVENCLAD® (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis

MAVENCLAD® (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis Eligible patients can access PrMAVENCLAD® through public drug plans in seven provinces and two federal programs MISSISSAUGA, ON, Oct. 27, 2020 /CNW/ – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and … Continue reading MAVENCLAD® (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis